Abstract
Genotype imputation, crucial in genomics research, often faces accuracy limitations, notably for rarer variants. Leveraging data from the 1000 Genomes Project, TOPMed and UK Biobank, we demonstrate that Selphi, our novel imputation method, significantly outperforms Beagle5.4, Minimac4 and IMPUTE5 across various metrics (12.5%-26.5% as measured by error count) and allele frequencies (13.0%-27.1% for low-frequency variants).This improvement in accuracy boosts variant discovery in GWAS and improves polygenic risk scores.
Competing Interest Statement
A.D.M., A.A.M., S.B., J.L.J., B.N., C.M., A.T, M. M. and P. G. Y. are either employed by and/or hold stock or stock options in Omics Edge, a subsidiary of Genius Labs. In addition, P.G.Y. has equity in Systomic Health LLC and Ethobiotics LLC. This does not alter our adherence to journal policies on sharing data and materials. There are no other relevant activities or financial relationships which have influenced this work.
Funding Statement
All work was funded by a commercial source, Omics Edge, a subsidiary of Genius Labs Company. Omics Edge provided only funding for the study, but had no additional role in study design, data collection and analysis, decision to publish or preparation of the manuscript beyond the funding of the contributors salaries.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used the openly available 1000 Genomes Project dataset and the UK Biobank and The Trans-Omics for Precision Medicine (TOPMed) datasets that are available to researchers upon application. UK Biobank research was conducted under application number 84038; Scripps team was granted access to TOPMed from NIH.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
No changes
Data availability
The complete documented Selphi code is available for testing for academic/non commercial use in the following GitHub repository: https://github.com/selfdecode/rd-imputation-selphi. Additionally, we offer an applet that allows users to conveniently test the Selphi code on the UKB RAP platform.
All publicly available datasets utilized in this study can be accessed through their original publications and via application to the UK Biobank. Furthermore, access to The Trans-Omics for Precision Medicine (TOPMed) dataset can be granted by the National Institutes of Health (NIH).
